These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 15480911)
21. Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank. Frank M Future Microbiol; 2022 Feb; 17(3):157-159. PubMed ID: 35044238 [No Abstract] [Full Text] [Related]
22. [Lung injury associated with bucillamine therapy]. Negishi M; Kaga S; Kasama T; Hashimoto M; Fukushima T; Yamagata N; Tabata M; Kobayashi K; Ide H; Takahashi T Ryumachi; 1992 Apr; 32(2):135-9. PubMed ID: 1595005 [TBL] [Abstract][Full Text] [Related]
23. [Clinicopathological evaluation and treatment of bucillamine induced membranous nephropathy]. Kikuchi M; Saeki T; Ito S; In H; Saito T; Ueno M; Sato T; Suzuki S; Nakano M; Ozawa T Ryumachi; 1993 Jun; 33(3):215-22. PubMed ID: 8346463 [TBL] [Abstract][Full Text] [Related]
25. Yellow nails under bucillamine therapy for rheumatoid arthritis: a report of two cases. Yamamoto T; Yokozeki H Rheumatol Int; 2007 Apr; 27(6):603-4. PubMed ID: 17103174 [No Abstract] [Full Text] [Related]
26. Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature. Isozaki T; Kimura M; Ikegaya N; Arai T; Fujigaki Y; Hishida A; Kaneko E Clin Investig; 1992 Nov; 70(11):1036-42. PubMed ID: 1472834 [TBL] [Abstract][Full Text] [Related]
32. Bucillamine-induced Pneumonitis in a Patient with Rheumatoid Arthritis-associated Interstitial Pneumonia: A Case Report and Review of the Literature. Fukada A; Toyoshima M; Nozue T; Suda T Intern Med; 2019 Aug; 58(15):2207-2211. PubMed ID: 30918198 [TBL] [Abstract][Full Text] [Related]